EcoDrugPlus

Amyloid Beta Precursor Protein

Ensembl ID : ENSAPOG00000008075
Gene Symbol: APP
4 Cross references
206 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSAPOG00000023292
Gene Symbol: AR
2 Cross references
214 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSAPOG00000007721
Gene Symbol: AGTR1
4 Cross references
202 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSAPOG00000014635
Gene Symbol: AGTR1
4 Cross references
202 Possible Orthologues:

Anti-Apoptotic Protein Nr13-Like

Ensembl ID : ENSAPOG00000021816
Gene Symbol: LOC110954827
3 Cross references
129 Possible Orthologues:

Apelin Receptor 2

Ensembl ID : ENSAPOG00000008697
Gene Symbol: APLNR2
1 Cross references
172 Possible Orthologues:

Apoptosis Regulator Bcl-2-Like

Ensembl ID : ENSAPOG00000006095
Gene Symbol: LOC110965865
2 Cross references
142 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSAPOG00000017002
Gene Symbol: APEX1
3 Cross references
214 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSAPOG00000019693
Gene Symbol: ALOX5
3 Cross references
212 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSAPOG00000019012
Gene Symbol: ALOX5AP
3 Cross references
201 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Like

Ensembl ID : ENSAPOG00000014110
Gene Symbol: LOC110963274
3 Cross references
200 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSAPOG00000018944
Gene Symbol: AVPR1A
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).